Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study

Xu, Jianming, Shen, Lin, Zhou, Zhiwei, Li, Jie, Bai, Chunmei, Chi, Yihebali, Li, Zhiping, Xu, Nong, Li, Enxiao, Liu, Tianshu, Bai, Yuxian, Yuan, Ying, Li, Xingya, Wang, Xiuwen, Chen, Jia, Ying, Jieer, Yu, Xianjun, Qin, Shukui, Yuan, Xianglin, Zhang, Tao, Deng, Yanhong, Xiu, Dianrong, Cheng, Ying, Tao, Min, Jia, Ru, Wang, Wei, Li, Jing, Fan, Songhua, Peng, Mengye, Su, Weiguo · 2020 · The Lancet Oncology

Abstract

BACKGROUND Therapeutic options for advanced neuroendocrine tumours (NETs) are limited. We investigated the efficacy and safety of surufatinib (HMPL-012, sulfatinib) in patients with extrapancreatic NETs. METHODS SANET-ep was a randomised, double-blind, placebo-controlled, phase 3 trial undertaken at 24 hospitals across China. Patients (aged 18 years or older) with unresectable or metastatic, well differentiated, extrapancreatic NETs, with an Eastern Cooperative Oncology Group performance status of 0 or 1, and progression on no more than two types of previous systemic regimens were enrolled. Patients were centrally randomly assigned (2:1) using stratified block randomisation (block size 3) via an interactive web response system to receive oral surufatinib at 300 mg per day or matching placebo. Randomisation was stratified by tumour origin, pathological grade, and previous treatment. Patients, investigators, research staff and the sponsor study team were masked to treatment allocation. Crossover to the surufatinib group was allowed for patients in the placebo group at disease progression. The primary endpoint was investigator-assessed progression-free survival, which was analysed in the intention-to-treat population. A preplanned interim analysis was done at 70% of predicted progression-free survival events. This study was registered with ClinicalTrials.gov, NCT02588170. Follow-up is ongoing. FINDINGS Between Dec 9, 2015, and March 31, 2019, 198 patients were randomly assigned to surufatinib (n=129) or placebo (n=69). Median follow-up was 13·8 months (95% CI 11·1-16·7) in the surufatinib group and 16·6 months (9·2-not calculable) in the placebo group. Investigator-assessed median progression-free survival was 9·2 months (95% CI 7·4-11·1) in the surufatinib group versus 3·8 months (3·7-5·7) in the placebo group (hazard ratio 0·33; 95% CI 0·22-0·50; p<0·0001). As the trial met the predefined criteria for early discontinuation of the study at the interim analysis, the study was terminated early, as recommended by the independent data monitoring committee. The most common treatment-related adverse events of grade 3 or worse were hypertension (47 [36%] of 129 patients in the surufatinib group vs nine [13%] of 68 patients in the placebo group) and proteinuria (25 [19%] vs zero). Treatment-related serious adverse events were reported in 32 (25%) of 129 patients in the surufatinib group and nine (13%) of 68 patients in the placebo group. Treatment-related deaths occurred in three patients in the surufatinib group (disseminated intravascular coagulation and hepatic encephalopathy, liver injury, and death with unknown reason) and one patient in the placebo group (cachexia and respiratory failure). INTERPRETATION Progression-free survival was significantly longer in patients given surufatinib compared with patients given placebo, and surufatinib has a favourable benefit-to-risk profile in patients with progressive, advanced, well differentiated extrapancreatic NETs. Our results suggest that surufatinib might be a new treatment option for this population. FUNDING Hutchison MediPharma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30496-4

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 196

Metadata

Authors
Xu, J., Shen, L., Zhou, Z., Li, J., Bai, C., Chi, Y., Li, Z., Xu, N., Li, E., Liu, T., Bai, Y., Yuan, Y., Li, X., Wang, X., Chen, J., Ying, J., Yu, X., Qin, S., Yuan, X., Zhang, T., Deng, Y., Xiu, D., Cheng, Y., Tao, M., Jia, R., Wang, W., Li, J., Fan, S., Peng, M., & Su, W.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-11
Volume
21
Issue
11
Pages
1500-1512
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3087682866
Cited by
196
References
2
FWCI
16.43
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30496-4
The paper
Xu, J., Shen, L., Zhou, Z., Li, J., Bai, C., Chi, Y., Li, Z., Xu, N., Li, E., Liu, T., Bai, Y., Yuan, Y., Li, X., Wang, X., Chen, J., Ying, J., Yu, X., Qin, S., Yuan, X., . . . Su, W. (2020). Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30496-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.